ACR24 IL-17 Panel Join Dr. Philip Mease, Dr. Brian Jaros and Dr. Peter Nash as they discuss key takeaways on IL-17 presentations and data presented at the 2024 ACR Convergence meeting in Washington, DC. https://t.co/04bW7vaMTQ https://t.co/0rTglbW75u

Navigating Rheumatology Care in Humanitarian Crisis Settings Dr. Antoni Chan talks with Dr. Martha Dhzhus, who presented Thursday at the Global Summit about rheumatology care in the Ukraine, at the 2024 ACR Convergence meeting in Washington, DC. https://t.co/k4YTVFnTiF https://t.co/bScrJ28rKi

Metabolic syndrome assoc w/ with response rates in #RA (CDAI MCID OR 0.6), on or off TNFi. Adipokines were associated with metabolic syndrome but were not associated with clinical responses. Data from CERTAIN cohort & CorEvitas registry https://t.co/YH44iTwYTr https://t.co/ec3vb266ym

Lancet forecasts that in Australia 5.4 million will have arthritis 2040, a 31% increase 4.1 mill in 2025. Included 3.2 w/ OA, ~750K w/ RA, & 8500 w/ JIA. OA incr in males from 6.3% to 7% (2040). & 10.8 to 12.2% in F. RA will grow from 1.56 to 1.75% in males and 2.6 to 2.9% in… https://t.co/6DM0ZLlZ05 https://t.co/djPP1cUDOI

Summary of JAKi Studies Dr. Peter Nash, at the 2024 ACR Convergence meeting in Washington, DC, talks about JAKi data presented in: the SELECT-GCA trial and safety signals; ILD; cancer; cycling; RA; uveitis; and new JAKs under study. https://t.co/ywmtrTi0iF https://t.co/nbFFojL1i4

Challenge in Measuring Cutaneous Lupus Activity and Severity JAMA Dermatology features a discussion by Drs. McMichael and Frey on measuring lupus skin disease in clinical trials and practice using the validated Cutaneous Lupus Erythematosus Disease Area and Severity Index… https://t.co/qyZPDzUduO https://t.co/cCoc3sWCJy

Infertility linked to post-childbrith onset of systemic autoimmune disease Women who experience infertility but do not use fertility treatments have a higher risk of developing a group of conditions called systemic autoimmune rheumatic diseases (SARD) in the nine years after a… https://t.co/NJf44KJ2Hc https://t.co/W4rhsDHoqB

BMJ has published an extensive, full read review of the Advances in the management of psoriatic arthritis in adults - by Drs. Gladman and Kharouf, (great read and reference!) https://t.co/4Bz3Vq93jH https://t.co/ZhwKZ4XmNy

JAMA FULL READ review and overview of Axial Spondyloarthritis by Drs. Deodhar & Bittar - Dx often delayed 6-8 yrs - Sensitivity/Specificity of: HLA-B27 (50%/90%), CRP (35%/91%), Xray sacroiliitis (66%/68%) or MRI (78%/88%). Great tables, figs, Xrays &Reference!… https://t.co/UbqVOr2iDx https://t.co/Ye5mYcbYX2

Fibroblastic Rheumatism - JAMA Case: 50yoM w/ 3 yr hx of periarticular nodules, symmetric polyarthralgia at B/L PIPs. These were painful with manipulation or minor trauma. Labs negative. https://t.co/dWvBjXgAIh https://t.co/YWmdqJrijf

Primary Hypophosphatemia (HYPOPH) - Japan study 50,136 adults w/ 424,434 alk phosphatase (ALP) tests. Persistent HYPOPH seen in 0.54% (273) due to cancer(30%), steroids(21%), DMARDs (16%). Unexplained HYPOPH had pain, muscle weakness, fatigue & could have primary HYPOPH… https://t.co/kGPSXSYEZI https://t.co/RtwSRnzeU0

Another Stelara (Ustekinumab) biosimilar was FDA approved on 12/1 -- called Yesintek for the treatment of Crohn’s, Ulcerative Colitis, Psoriasis & PsA. This makes 6 FDA approved biosimilars for ustekinumab.https://t.co/SMKx1LnBB1 https://t.co/96u5YuvyIf